Introduction {#s1}
============

As one of the most common malignant tumors of the urinary system, bladder cancer (BC) is estimated to cause about 549,393 new cases and 199,922 deaths worldwide in 2018 ([@B1]). Based on the clinic-pathological features, BC could be classified into two types: non-muscle invasive tumor (NMIBC, 70--80% of BC patient) and muscle-invasive tumor (MIBC, 20--30% of BC patient) ([@B2], [@B3]). Due to the relatively high rate of local recurrence and metastasis in MIBC patients, the treatment outcome is still poor, and the survival rate is lower than that of NMIBC patients. Although NMIBC patients have better survival rates than MIBC, 30--50% of NMIBC patients experience cancer recurrence ([@B4]). One of the major challenges to improve clinical outcomes of BC patients is to screen novel biomarkers for diagnosis and prognosis ([@B5]).

In recent years, a large number of prognostic biomarkers including DNA markers and protein markers have been reported ([@B6]--[@B8]). Some of the prognostic biomarkers, especially the ones involved in biological processes, are useful to identify high-risk patients, and could be used to predict the prognosis and treatment response. However, few biomarkers have been translated into clinics due to the lack of independent validation ([@B5], [@B9], [@B10]). With the advance of high through-put technologies, more and more studies analyzed the gene expression of cancer samples and uploaded these data on public databases such as The Cancer Genome Atlas (TCGA, <https://portal.gdc.cancer.gov/>) and Gene Expression Omnibus (GEO, <https://www.ncbi.nlm.nih.gov/geo/>). These data offer opportunities for the biomarker discovery, validation, and clinical application ([@B11], [@B12]). Unfortunately, until now, this convenient online tool is still unavailable to clinicians and biologists to evaluate and verify the prognostic value of the genes of interests in different datasets for BC.

To solve this problem, we developed an online web server named OSblca, which consists of gene expression profiles and relative clinical information of 1,075 bladder cancer patients from seven independent cohorts collected from TCGA and GEO databases. This web server enables researchers and clinicians to analyze the prognostic value of a gene of interest and accelerates the development of prognostic biomarkers.

Methods {#s2}
=======

Datasets Collection
-------------------

Gene expression profiles and clinical follow-up information of bladder cancer patients were collected from TCGA and GEO databases. For TCGA dataset, level-3 gene expression profiling data (HiSeqV2) and clinical information of BC samples were downloaded in April 2018. In order to collect the relative datasets from GEO, keywords including "bladder cancer," "prognosis," "survival," and "gene expression" were used to search in GEO database. Next, manual checks of the availability of data of mRNA expression, clinical survival information and at least 50 patients were performed.

Development of OSblca
---------------------

The OSblca web server was developed by Java script, and hosted by Tomcat 7.0 on Windows 2008. The database system that stores the gene expression and clinical data was handled by SQL Server 2008. The R package "RODBC" is used as a middleware to connect R and SQL. The input of OSblca web server must be the official gene symbol from NCBI (<https://www.ncbi.nlm.nih.gov/>). The outputs include Kaplan Meier (KM) survival curves, Hazard ratio (HR with 95% confidence interval) and log-rank *P*-value that are produced by R package "survival" (<https://CRAN.R-project.org/package=survival>). A gene could be regarded as a potential prognostic biomarker for BC patients when the log-rank *P*-value is \< 0.05. OSblca can be accessed at <http://bioinfo.henu.edu.cn/BLCA/BLCAList.jsp>. A web server architecture diagram is presented in [Figure 1A](#F1){ref-type="fig"}. The screenshot of the web server interface and the result are shown in [Figure 1B](#F1){ref-type="fig"}.

![Diagram of web server architecture **(A)** and screenshot of OSblca main interface **(B)**.](fonc-09-00466-g0001){#F1}

Validation of Previously Published Prognostic Biomarkers in OSblca
------------------------------------------------------------------

In order to validate the performance of prognostic analysis in our web server, prognosis biomarkers for BC were searched in PubMed using the keywords "bladder cancer," "survival," "gene expression," "biomarker," and "prognosis." The prognostic capabilities of these genes were evaluated in all cohorts, and all cutoff values in "splitting the patients" were tested in each cohort to get the best cutoff value.

Results {#s3}
=======

Clinical Characteristics of the Patients in OSblca
--------------------------------------------------

According to our criteria, in total 1,075 unique bladder cancer patients were collected from seven data sets including one TCGA cohort and six GEO cohorts. Survival information including overall survival (OS), disease specific survival (DSS), disease free interval (DFI), progression free interval (PFI) were gathered. No patient was lost to follow-up. Of the above, 935 patients have overall survival information, and the median overall survival time is 25.03 months. We also collected age, TNM stage, histological type, gender, smoking history, lymph invasion and race as confounding clinical factors. The average age is 68 ± 11. Distribution of TNM stages is as follows: stage I (*n* = 287, 29.64%), stage II (*n* = 233, 23.26%), stage III (*n* = 239, 23.85%), and stage IV (*n* = 209, 20.86%). The ratio of male to female of patients was close to 3:1. A summary of clinical properties for each dataset is presented in [Table 1](#T1){ref-type="table"}.

###### 

Clinical characteristics of the BC patients collected in OSblca.

  **Data source**   **Platform**       **Sample size**   **Age**   **No. of death**   **Media (OS)**   **Gender (% male)**   **Stage (%I/II/III/IV/NA[^a^](#TN1){ref-type="table-fn"})**   **Never smokers (%)**   **Survival terms**
  ----------------- ------------------ ----------------- --------- ------------------ ---------------- --------------------- ------------------------------------------------------------- ----------------------- ----------------------------------------------------
  TCGA              Illumina HiSeqV2   407               69 ± 11   155                16.93            73.71                 0.49/31.70/34.40/32.92/0.49                                   26.78                   OS, DSS, DFI, PFI[^\*^](#TN2){ref-type="table-fn"}
  GSE13507          GPL6102            165               65 ± 12   69                 36.57            --                    48.48/15.76/11.52/10.30/13.94                                 --                      OS
  GSE19915          GPL3883/GPL5186    140                         24                 --               --                    69.29/12.14/15.00/2.14/1.43                                   --                      DSS
  GSE31684          GPL570             93                69 ± 10   65                 31.31            71.12                 16.13/18.28/45.16/20.43/0.00                                  19.35                   OS, DSS, DFI, PFI
  GSE32548          GPL6947            130               70 ± 11   25                 53.77            76.15                 70.00/29.23/0.00/0.00/0.77                                    --                      OS, DSS, DFI, PFI
  GSE48075          GPL6947            73                69 ± 10   45                 30.40            --                    --                                                            --                      OS
  GSE48276          GPL14951           67                          31                 34.10            80.60                 2.99/8.96/25.37/53.73/8.95                                                            OS, DSS
  Total                                1075              68 ± 11   414                25.03            74.46                 29.64/23.26/23.85/20.86/3.39                                  11.81                   

NA, Not Available;

"--," no data;

*DFI and PFI were defined by ([@B13])*.

Survival Analysis of BC Patients Based on Clinical Characteristics
------------------------------------------------------------------

The Kaplan-Meier plots for the bladder cancer patients in OSblca stratified by TNM stage, histological type, gender, smoking history, lymph invasion, and race are presented in [Figure 2](#F2){ref-type="fig"}. In these 1,075 patients, TNM stage, smoking history, lymph invasion, and histological type were significantly associated with overall survival (*P* \< 0.0001, *P* = 0.0206, *P* \< 0.0001, and *P* \< 0.0001, respectively), which were consistent with previously reports ([@B14]--[@B16]). Nevertheless, gender and race showed no significant association with overall survival (*P* = 0.2260 and *P* = 0.5513).

![Survival analysis of clinical characteristics of the bladder cancer patients in OSblca. **(A)** TNM stage; **(B)** Lymph invasion; **(C)** Smoking history; **(D)** Histological type; **(E)** Gender; **(F)** Race.](fonc-09-00466-g0002){#F2}

Usage of OSblca
---------------

The main function that OSblca provides is to evaluate and verify the prognostic value for a given gene. "Gene symbol," "Data source," "Survival," and "Split patients" are set as the four main parameters. The input dialog box of "Gene symbol" is on the upper left of the OSblca page ([Figure 3A](#F3){ref-type="fig"}). A red prompting message will show up when the input is not an official gene symbol. "Data source" provides eight options including independent analysis in one of seven cohorts and in a combined cohort consisting of all the BC patients from seven cohorts. The users can choose to evaluate the prognosis of a given gene in an individual cohort or in a combined cohort according to their needs. Under "Survival" option, four prognostic terms including OS, DSS, DFI, and PFI are provided. In the "Split patients" dialog box, user can select different thresholds of gene expression levels to divide patients into two subgroups for input gene. After then, by clicking the "Kaplan-Meier plot" button, OSblca server will take the request and return the analysis results, which are graphically displayed and presented with HR, 95% CI and log-rank *P*-value ([Figure 3B](#F3){ref-type="fig"}).

![Input and output interface of OSblca. **(A)** The options of main input parameters and clinical factors of OSblca; **(B)** The output interface of OSblca.](fonc-09-00466-g0003){#F3}

In order to meet the specific needs, six confounding clinical factors including TNM stage, smoking history, gender, lymph, histological type, and race, were set as optional filter factors in the prognostic analysis. As showed in [Figure 3A](#F3){ref-type="fig"}, each factor has 2--5 options for users to choose from.

Validation of Previously Published BC Biomarkers
------------------------------------------------

To test the reliability of prognosis prediction in our web server, we evaluated 21 prognostic biomarkers from 16 previously reported literatures in the OSblca web server, including *KPNA2, TP53*, and *MYC* ([@B17]--[@B32]). As shown in [Table 2](#T2){ref-type="table"}, 17 out of 21 (82%) previous reported prognostic biomarkers were showed to have significant prognostic potency in OSblca, while the remaining four previously reported prognostic biomarkers did not reach significance in OSblca. Among the 17 validated prognostic biomarkers, 11 genes showed significant prognostic abilities in the combined cohort.

###### 

The validation of previous reported prognostic biomarkers in OSblca.

  **Gene symbol**   **Detection level**   **Case**   **Independent validation**   **In reference**   **In OSblca**                                                             
  ----------------- --------------------- ---------- ---------------------------- ------------------ --------------- ---------- --------------------------------------- ------ -----------
  *KPNA2*           Protein               611        Yes                          0.030              1.38            ([@B17])   0.001[^a^](#TN3){ref-type="table-fn"}   1.42   Upper 25%
  *HYAL1*           Protein               220        Yes                          0.019              1.76            ([@B18])   0.021[^a^](#TN3){ref-type="table-fn"}   1.29   Upper 25%
  *TP53*            Protein               152        No                           \< 0.001           --              ([@B19])   0.037[^a^](#TN3){ref-type="table-fn"}   0.77   Upper 25%
  *MYC*             Protein               132        No                           0.020              --              ([@B20])   0.050[^a^](#TN3){ref-type="table-fn"}   1.25   Upper 25%
  *RPS6*            Protein               132        No                           \< 0.010           --              ([@B20])   0.007[^a^](#TN3){ref-type="table-fn"}   0.71   Upper 25%
  *JMJD2A*          Protein               129        No                           0.033              --              ([@B21])   0.026[^a^](#TN3){ref-type="table-fn"}   0.63   Upper 25%
  *MKi67*           Protein               115        No                           \< 0.050           --              ([@B22])   0.021[^a^](#TN3){ref-type="table-fn"}   1.29   Upper 25%
  *RRM1*            Protein               84         No                           0.001              --              ([@B23])   0.000[^a^](#TN3){ref-type="table-fn"}   1.68   Lower 25%
  *MMP2*            mRNA                  41         No                           \< 0.05            --              ([@B25])   0.039[^a^](#TN3){ref-type="table-fn"}   1.26   Upper 25%
  *CDH2*            mRNA                  181        No                           \< 0.001           --              ([@B26])   0.038[^a^](#TN3){ref-type="table-fn"}   1.26   Upper 25%
  *PTGS2*           Protein               273        No                           0.027              0.65            ([@B24])   0.050[^b^](#TN4){ref-type="table-fn"}   0.72   Upper 25%
  *CDH3*            mRNA                  181        No                           \< 0.010           --              ([@B26])   0.041[^c^](#TN5){ref-type="table-fn"}   2.30   Upper 25%
  *MDM2*            Protein               84         No                           \< 0.050                           ([@B27])   0.045[^d^](#TN5){ref-type="table-fn"}   1.89   Upper 25%
  *CCND3*           Protein               157        No                           \< 0.030           --              ([@B28])   0.039[^c^](#TN5){ref-type="table-fn"}   2.32   Upper 25%
  *CCND2*           Protein               57         No                           0.042              --              ([@B28])   0.047[^f^](#TN5){ref-type="table-fn"}   1.67   Lower 25%
  *LGALS3*          mRNA                  165        Yes                          \< 0.001           --              ([@B29])   0.016[^e^](#TN5){ref-type="table-fn"}   0.61   Lower 25%
  *USP28*           Protein               206        Yes                          \< 0.001           --              ([@B30])   0.048[^c^](#TN5){ref-type="table-fn"}   0.29   Lower 30%
                                                                                                                                0.014[^d^](#TN5){ref-type="table-fn"}   0.38   Lower 30%
  *DIABLO*          Protein               84         No                           \< 0.050           --              ([@B31])   0.239[^g^](#TN6){ref-type="table-fn"}   0.87   NA
  *RB1*             Protein               311        No                           0.030              --              ([@B25])   0.898[^g^](#TN6){ref-type="table-fn"}   1.02   NA
  *FGFR3*           mRNA                  114        No                           0.035              --              ([@B32])   0.462[^g^](#TN6){ref-type="table-fn"}   0.92   NA
  *CCND1*           Protein               157        No                           \< 0.020           --              ([@B28])   0.997[^g^](#TN6){ref-type="table-fn"}   0.98   NA

Significant P-value validated in a combined cohort (OS);

Significant P-value validated in a combined cohort (DSS);

Significant P-value validated in dataset GSE32548, GSE48075, TCGA, and GSE13507, respectively;

*No significance P-value validated in any cohorts, "--" means no HR data, "NA" means not applicable*.

Discussion {#s4}
==========

The discovery of prognostic biomarkers is a hot topic in translational research. In the current study, we present a convenient web server to assist researchers and clinicians to quickly screen and evaluate the prognostic value of genes in different cohorts of BC. As shown in a straightforward web interface, people without much bioinformatics experience can easily navigate OSblca to investigate genes of interests. In addition, users can perform survival analysis filtered by one or several factors according to the specific research purposes of their needs.

The validation of previously reported prognostic biomarkers in OSblac showed that our web tool is reliable and can be used in prognostic analysis for BC patients. Notably, 11 genes, such as *KPNA2* and *TP53*, were confirmed as prognostic biomarkers in the combined cohort, which indicated that these genes may be more widely applied as prognostic candidates for BC patients.

In summary, OSblca is a free online survival analysis web server that allows clinicians and researchers to rapidly analyze the prognostic value of a given gene in BC. We will keep updating OSblca to make it more powerful for the users.
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